Clinical Characteristics and Outcomes of Patients with Culture-Negative Pyogenic Spondylitis according to Empiric Glycopeptide Use
2
조회
0
다운로드
1
인용
0
참고문헌
키워드
초록
Background: The optimal choice of antibiotics is challenging in culture-negative pyogenic spondylitis (PS). The empiric use of glycopeptides is suggested depending on various risk factors, although clinical data are sparse. This study aimed to analyze the clinical characteristics and outcomes of patients with culture-negative PS and evaluate the effect of empiric glycopeptide use on clinical outcomes in these patients. Materials and Methods: Data on the characteristics, treatment, and outcomes of 175 patients diagnosed with PS were retrospectively obtained from the electronic database of a tertiary referral hospital from 2009 to 2016. Patients with negative culture results were grouped by the duration of glycopeptide treatment: glycopeptide therapy <28 days (Group A) and glycopeptide therapy ≥28 days (Group B). Results: Of 89 patients with negative culture results, 78 were included in the analysis (Group A, n = 66; Group B, n = 12). The mean age of patients with negative culture results was 65.5 years, and 52.6% were male. The median follow-up duration was 573 (interquartile range [IQR], 83 – 1,037) days. The duration of intravenous glycopeptide therapy was 0.0 (IQR, 0.0 – 0.0) days and 55.5 (IQR, 37.0 – 75.7) days for Groups A and B, respectively. Patients who used glycopeptide longer empirically (Group B) had more commonly undergone a previous spinal procedure, including surgery (P = 0.024). The length of hospitalization, erythrocyte sedimentation rate, and C-reactive protein level were significantly higher in Group B compared with those in Group A (P <0.001, P <0.001, and P = 0.006, respectively). Regarding treatment modalities, patients in Group B underwent surgery more frequently (P = 0.017). The duration of parenteral antibiotic treatment was longer in Group B (P <0.001). Recurrence was noted in 7 patients (9.0%), and the recurrence rate was not significantly different between the 2 groups (Group A, 5/66 [7.6%]; Group B, 2/12 [16.7%]; P = 0.293). Conclusion: The recurrence rate among patients with culture-negative PS was not different based on the duration of empiric glycopeptide use. However, considering the small sample size and heterogeneity of our study population, we suggest that it is reasonable to administer glycopeptide antibiotics in these patients depending on clinical risk factors. Further large-scale prospective studies are needed to obtain more evidence for appropriate antibiotic treatment.
Abstract
Background: The optimal choice of antibiotics is challenging in culture-negative pyogenic spondylitis (PS). The empiric use of glycopeptides is suggested depending on various risk factors, although clinical data are sparse. This study aimed to analyze the clinical characteristics and outcomes of patients with culture-negative PS and evaluate the effect of empiric glycopeptide use on clinical outcomes in these patients. Materials and Methods: Data on the characteristics, treatment, and outcomes of 175 patients diagnosed with PS were retrospectively obtained from the electronic database of a tertiary referral hospital from 2009 to 2016. Patients with negative culture results were grouped by the duration of glycopeptide treatment: glycopeptide therapy <28 days (Group A) and glycopeptide therapy ≥28 days (Group B). Results: Of 89 patients with negative culture results, 78 were included in the analysis (Group A, n = 66; Group B, n = 12). The mean age of patients with negative culture results was 65.5 years, and 52.6% were male. The median follow-up duration was 573 (interquartile range [IQR], 83 – 1,037) days. The duration of intravenous glycopeptide therapy was 0.0 (IQR, 0.0 – 0.0) days and 55.5 (IQR, 37.0 – 75.7) days for Groups A and B, respectively. Patients who used glycopeptide longer empirically (Group B) had more commonly undergone a previous spinal procedure, including surgery (P = 0.024). The length of hospitalization, erythrocyte sedimentation rate, and C-reactive protein level were significantly higher in Group B compared with those in Group A (P <0.001, P <0.001, and P = 0.006, respectively). Regarding treatment modalities, patients in Group B underwent surgery more frequently (P = 0.017). The duration of parenteral antibiotic treatment was longer in Group B (P <0.001). Recurrence was noted in 7 patients (9.0%), and the recurrence rate was not significantly different between the 2 groups (Group A, 5/66 [7.6%]; Group B, 2/12 [16.7%]; P = 0.293). Conclusion: The recurrence rate among patients with culture-negative PS was not different based on the duration of empiric glycopeptide use. However, considering the small sample size and heterogeneity of our study population, we suggest that it is reasonable to administer glycopeptide antibiotics in these patients depending on clinical risk factors. Further large-scale prospective studies are needed to obtain more evidence for appropriate antibiotic treatment.
참고문헌 (19)
- Gouliouris T, "Spondylodiscitis: update on diagnosis and management", J Antimicrob Chemother, 65(Suppl 3), pp.iii11~iii24 (2010)
- Boody BS, "Vertebral osteomyelitis and spinal epidural abscess: an evidence-based review", J Spinal Disord Tech, 28, pp.E316~E327 (2015)
- Nickerson EK, "Vertebral osteomyelitis in adults : an update", Br Med Bull, 117, pp.121~138 (2016)
- 정희진, "Clinical Guidelines for the Antimicrobial Treatment of Bone and Joint Infections in Korea", Infection and Chemotherapy, 46(2), pp.125~138 (2014), 대한감염학회
- Park KH, "Clinical characteristics and therapeutic outcomes of hematogenous vertebral osteomyelitis caused by methicillin-resistant Staphylococcus aureus", J Infect, 67, pp.556~564 (2013)
- "Statistical brief #35: Infections with methicillin-resistant Staphylococcus aureus (MRSA) in U.S. hospitals, 1993–2005"[URL]
- Bhagat S, "Spondylodiscitis(disc space infection)associated with negative microbiological tests : comparison of outcome of suspected disc space infections to documented non-tuberculous pyogenic discitis", Br J Neurosurg, 21, pp.473~477 (2007)
- Lora-Tamayo J, "Changing trends in the epidemiology of pyogenic vertebral osteomyelitis : the impact of cases with no microbiologic diagnosis", Semin Arthritis Rheum, 41, pp.247~255 (2011)
- Kim J, "Outcome of culturenegative pyogenic vertebral osteomyelitis : comparison with microbiologically confirmed pyogenic vertebral osteomyelitis", Semin Arthritis Rheum, 44, pp.246~252 (2014)
- Kehrer M, "Increasing incidence of pyogenic spondylodiscitis : a 14-year population-based study", J Infect, 68, pp.313~320 (2014)
- Pigrau C, "Spontaneous pyogenic vertebral osteomyelitis and endocarditis: incidence, risk factors, and outcome", Am J Med, 118, pp.1287~ (2005)
- Mustapić M, "Vertebral osteomyelitis in adult patients-characteristics and outcome", Acta Clin Croat, 55, pp.9~15 (2016)
- Berbari EF, "2015 Infectious Diseases Society of America (IDSA) clinical practice guidelines for the diagnosis and treatment of native vertebral osteomyelitis in adults", Clin Infect Dis, 61, pp.e26~e46 (2015)
- Hopkinson N, "A case ascertainment study of septic discitis: clinical, microbiological and radiological features", QJM, 94, pp.465~470 (2001)
- Yoon SH, "Pyogenic vertebral osteomyelitis : identification of microorganism and laboratory markers used to predict clinical outcome", Eur Spine J, 19, pp.575~582 (2010)
- Viale P, "Treatment of pyogenic(non-tuberculous)spondylodiscitis with tailored high-dose levofloxacin plus rifampicin", Int J Antimicrob Agents, 33, pp.379~382 (2009)
- Luzzati R, "Diagnosis, management and outcome of clinically- suspected spinal infection", J Infect, 58, pp.259~265 (2009)
- Zimmerli W, "Clinical practice. Vertebral osteomyelitis", N Engl J Med, 362, pp.1022~1029 (2010)
- Parikh MS, "A comprehensive review of the diagnosis and management of prosthetic joint infections in the absence of positive cultures", J Infect Public Health, 9, pp.545~556 (2016)